Cellular iron homeostasis and therapeutic implications of iron chelators in cancer

Current Pharmaceutical Biotechnology

Volumn 15, Issue 12, 2014, Pages 1125-1140

  Raza, Mohsin ^a   Chakraborty, Sankalpa ^a   Choudhury, Monjoy ^a   Ghosh, Prahlad C ^a   Nag, Alo ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Cancer; Homeostasis; Iron chelator; Iron metabolism

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; CATECHIN; CERULOPLASMIN; CURCUMIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; HEPCIDIN; IRON REGULATORY FACTOR; KOLAVIRON; PROTON COUPLED FOLATE TRANSPORTER; QUERCETIN; SOYBEAN PROTEIN; IRON; IRON CHELATING AGENT;

ANEMIA; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONGESTIVE HEART FAILURE; DNA SYNTHESIS; GENE MUTATION; GENETIC REGULATION; HOMEOSTASIS; HUMAN; HYPOXIA; IRON CHELATION; IRON HOMEOSTASIS; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; NEOPLASM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; NEOPLASMS;

ANIMALS; HOMEOSTASIS; HUMANS; IRON; IRON CHELATING AGENTS; NEOPLASMS;

EID: 84926350246     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920101512141202111915     Document Type: Article

References (226)

1. DeBruyne, L. Iron deficiency in athletes. Nutrit. Clin., 1991, 6.
2. Hentze, M.W.; Muckenthaler, M.U.; Andrews, N.C. Balancing acts: Molecular control of mammalian iron metabolism. Cell, 2004, 117(3), 285-297.
3. Theil, E.C. Iron regulatory elements (IREs): a family of mRNA non-coding sequences. Biochem. J., 1994, 304(Pt 1), 1-11.
4. Lawen, A.; Lane, D.J. Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid. Redox. Signal., 2013, 18(18), 2473-2507.
5. Torti, S.V.; Torti, F.M. Iron and cancer: More ore to be mined. Nat. Rev. Cancer., 2013, 13(5), 342-355.
6. Heli, H.; Mirtorabi, S.; Karimian, K. Advances in iron chelation: an update. Expert Opin. Ther. Pat., 2011, 21(6), 819-856.
7. Pantopoulos, K.; Porwal, S.K.; Tartakoff, A.; Devireddy, L. Mechanisms of mammalian iron homeostasis. Biochem., 2012, 51(29), 5705-5724.
8. Shayeghi, M.; Latunde-Dada, G.O.; Oakhill, J.S.; Laftah, A.H.; Takeuchi, K.; Halliday, N.; Khan, Y.; Warley, A.; McCann, F.E.; Hider, R.C.; Frazer, D.M.; Anderson, G.J.; Vulpe, C.D.; Simpson, R.J.; McKie, A.T. Identification of an intestinal heme transporter. Cell, 2005, 122(5), 789-801.
9. McKie, A.T.; Barrow, D.; Latunde-Dada, G.O.; Rolfs, A.; Sager, G.; Mudaly, E.; Mudaly, M.; Richardson, C.; Barlow, D.; Bomford, A.; Peters, T.J.; Raja, K.B.; Shirali, S.; Hediger, M.A.; Farzaneh, F.; Simpson, R.J. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science, 2001, 291(5509), 1755-1759.
10. Gunshin, H.; Mackenzie, B.; Berger, U.V.; Gunshin, Y.; Romero, M.F.; Boron, W.F.; Nussberger, S.; Gollan, J.L.; Hediger, M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature, 1997, 388(6641), 482-488.
11. Harris, Z.L.; Durley, A.P.; Man, T.K.; Gitlin, J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci., 1999, 96(19), 10812-10817.
12. Kawabata, H.; Yang, R.; Hirama, T.; Vuong, P.T.; Kawano, S.; Gombart, A.F.; Koeffler, H.P. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J. Biologic. Chem., 1999, 274(30), 20826-20832.
13. Netz, D.J.; Stith, C.M.; Stümpfig, M.; Köpf, G.; Vogel, D.; Genau, H.M.; Stodola, J.L.; Lill, R.; Burgers, P. M.; Pierik, A.J. Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of active complexes. Nat. Chem. Biol., 2012, 8(1), 125-132.
14. Pondarre, C.; Antiochos, B.B.; Campagna, D.R.; Clarke, S.L.; Greer, E.L.; Deck, K.M.; McDonald, A.; Han, A.P.; Medlock, A.; Kutok, J.L.; Anderson, S.A.; Eisenstein, R.S.; Fleming, M.D. The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. Human Molecul. Genet., 2006, 15(6), 953-964.
15. Cavadini, P.; Biasiotto, G.; Poli, M.; Levi, S.; Verardi, R.; Zanella, I.; Derosas, M.; Ingrassia, R.; Corrado, M.; Arosio, P. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood, 2007, 109(8), 3552-3559.
16. Paradkar, P.N.; Roth, J.A. Post-translational and transcriptional regulation of DMT1 during P19 embryonic carcinoma cell differentiation by retinoic acid. Biochem. J., 2006, 394(Pt 1), 173-183.
17. Wang, J.; Pantopoulos, K. Regulation of cellular iron metabolism. Biochem. J., 2011, 434(3), 365-381.
18. Zhang, A.S.; Sheftel, A.D.; Ponka, P. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood, 2005, 105(1), 368-375.
19. Kumar, A.; Nag, M.; Basak, S. Truncated or 2/2 Hemoglobins: a new class of globins with novel structure and function. J. Proteins Proteom., 2013, 4(1).
20. Kumar, A.; Uppal, S.; Kundu, S. The red goldmine: promises of biotechnological riches. Biotechnol. Applicat., 2009, 230.
21. Johnson, D.C.; Dean, D.R.; Smith, A.D.; Johnson, M.K. Structure, function, and formation of biological iron-sulfur clusters. Annu. Rev. Biochem., 2005, 74, 247-281.
22. Meyer, J. Iron-sulfur protein folds, iron-sulfur chemistry, and evolution. J. Biol. Inorg. Chem.: JBIC, 2008, 13(2), 157-170.
23. Rudolf, J.; Makrantoni, V.; Ingledew, W.J.; Stark, M.J.; White, M.F. The DNA repair helicases XPD and FancJ have essential ironsulfur domains. Molecul. Cell, 2006, 23(6), 801-808.
24. Beinert, H. Iron-sulfur proteins: ancient structures, still full of surprises. J. Biol. Inorg. Chem., 2000, 5(1), 2-15.
25. Booker, S.J.; Cicchillo, R.M.; Grove, T.L. Self-sacrifice in radical S-adenosylmethionine proteins. Curr. Opin. Chemic. Biol., 2007, 11(5), 543-552.
26. Volz, K. The functional duality of iron regulatory protein 1. Curr. Opin. Struc. Biol., 2008, 18(1), 106-111.
27. Yoon, T.; Cowan, J.A. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biologic. Chem., 2004, 279(25), 25943-25946.
28. Gonzalez-Cabo, P.; Vazquez-Manrique, R.P.; Garcia-Gimeno, M.A.; Sanz, P.; Palau, F. Frataxin interacts functionally with mitochondrial electron transport chain proteins. Human Mol. Genet., 2005, 14(15), 2091-2098.
29. Shan, Y.; Napoli, E.; Cortopassi, G. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Human Mol. Genet., 2007, 16(8), 929-941.
30. MacKenzie, E.L.; Iwasaki, K.; Tsuji, Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid. Redox. Signal, 2008, 10(6), 997-1030.
31. Ferreira, C.; Bucchini, D.; Martin, M.E.; Levi, S.; Arosio, P.; Grandchamp, B.; Beaumont, C. Early embryonic lethality of H ferritin gene deletion in mice. J. Biol. Chem., 2000, 275(5), 3021-3024.
32. Cozzi, A.; Corsi, B.; Levi, S.; Santambrogio, P.; Biasiotto, G.; Arosio, P. Analysis of the biologic functions of H-and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood, 2004, 103(6), 2377-2383.
33. Lind, M.I.; Missirlis, F.; Melefors, O.; Uhrigshardt, H.; Kirby, K.; Phillips, J.P.; Soderhall, K.; Rouault, T.A. Of two cytosolic aconitases expressed in Drosophila, only one functions as an ironregulatory protein. J. Biol. Chem., 2006, 281(27), 18707-18714.
34. Morton, A.G.; Tavill, A.S. The role of iron in the regulation of hepatic transferrin synthesis. Brit. J. Haematol., 1977, 36(3), 383-394.
35. Ganz, T. Hepcidin and iron regulation, 10 years later. Blood, 2011, 117(17), 4425-4433.
36. Babitt, J.L.; Huang, F.W.; Wrighting, D.M.; Xia, Y.; Sidis, Y.; Samad, T.A.; Campagna, J.A.; Chung, R.T.; Schneyer, A.L.; Woolf, C.J.; Andrews, N.C.; Lin, H.Y. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet., 2006, 38(5), 531-539.
37. Park, K.M.; Chen, A.; Bonventre, J.V. Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J. Biol. Chem., 2001, 276(15), 11870-11876.
38. Nicolas, G.; Chauvet, C.; Viatte, L.; Danan, J.L.; Bigard, X.; Devaux, I.; Beaumont, C.; Kahn, A.; Vaulont, S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Investig., 2002, 110(7), 1037-1044.
39. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004, 306(5704), 2090-2093.
40. De Domenico, I.; Ward, D.M.; Langelier, C.; Vaughn, M.B.; Nemeth, E.; Sundquist, W.I.; Ganz, T.; Musci, G.; Kaplan, J. The molecular mechanism of hepcidin-mediated ferroportin downregulation. Mol. Biol. Cell, 2007, 18(7), 2569-2578.
41. Bishop, G.M.; Robinson, S.R.; Liu, Q.; Perry, G.; Atwood, C.S.; Smith, M.A. Iron: A pathological mediator of Alzheimer disease? Developmen. Neurosci., 2002, 24(2-3), 184-187.
42. Kaur, D.; Andersen, J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev., 2004, 3(3), 327-343.
43. Trinder, D.; Fox, C.; Vautier, G.; Olynyk, J.K. Molecular pathogenesis of iron overload. Gut, 2002, 51(2), 290-295.
44. Kolnagou, A.; Michaelides, Y.; Kontos, C.; Kyriacou, K.; Kontoghiorghes, G.J. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin, 2008, 32(1-2), 17-28.
45. Jazwinska, E.C.; Cullen, L.M.; Busfield, F.; Pyper, W.R.; Webb, S.I.; Powell, L.W.; Morris, C.P.; Walsh, T.P. Haemochromatosis and HLA-H. Nat. Genet., 1996, 14(3), 249-251.
46. Feder, J.N.; Gnirke, A.; Thomas, W.; Tsuchihashi, Z.; Ruddy, D.A.; Basava, A.; Dormishian, F.; Domingo, R., Jr.; Ellis, M.C.; Fullan, A.; Hinton, L.M.; Jones, N.L.; Kimmel, B.E.; Kronmal, G.S.; Lauer, P.; Lee, V.K.; Loeb, D.B.; Mapa, F.A.; McClelland, E.; Meyer, N.C.; Mintier, G.A.; Moeller, N.; Moore, T.; Morikang, E.; Prass, C.E.; Quintana, L.; Starnes, S.M.; Schatzman, R.C.; Brunke, K.J.; Drayna, D.T.; Risch, N.J.; Bacon, B.R.; Wolff, R.K. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet., 1996, 13(4), 399-408.
47. Roetto, A.; Totaro, A.; Piperno, A.; Piga, A.; Longo, F.; Garozzo, G.; Cali, A.; De Gobbi, M.; Gasparini, P.; Camaschella, C. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood, 2001, 97(9), 2555-2560.
48. Njajou, O.T.; Vaessen, N.; Joosse, M.; Berghuis, B.; van Dongen, J.W.; Breuning, M.H.; Snijders, P.J.; Rutten, W.P.; Sandkuijl, L.A.; Oostra, B.A.; van Duijn, C.M.; Heutink, P. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat. Genet., 2001, 28(3), 213-214.
49. Hahn, P.; Qian, Y.; Dentchev, T.; Chen, L.; Beard, J.; Harris, Z.L.; Dunaief, J.L. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc. Nat. Acad. Sci. USA, 2004, 101(38), 13850-13855.
50. Weinstein, D.A.; Roy, C.N.; Fleming, M.D.; Loda, M.F.; Wolfsdorf, J.I.; Andrews, N.C. Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood, 2002, 100(10), 3776-3781.
51. Nicolas, G.; Chauvet, C.; Viatte, L.; Danan, J.L.; Bigard, X.; Devaux, I.; Beaumont, C.; Kahn, A.; Vaulont, S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Investig., 2002, 110(7), 1037-1044.
52. Richardson, D.R.; Mouralian, C.; Ponka, P.; Becker, E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophy. Acta, 2001, 1536(2-3), 133-140.
53. Lill, R. Function and biogenesis of iron-sulphur proteins. Nat., 2009, 460(7257), 831-838.
54. Larrick, J.W.; Cresswell, P. Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J. Supramol. Struct., 1979, 11(4), 579-586.
55. Hubert, R.S.; Vivanco, I.; Chen, E.; Rastegar, S.; Leong, K.; Mitchell, S.C.; Madraswala, R.; Zhou, Y.; Kuo, J.; Raitano, A.B.; Jakobovits, A.; Saffran, D.C.; Afar, D.E. STEAP: a prostatespecific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. USA, 1999, 96(25), 14523-14528.
56. Ohgami, R.S.; Campagna, D.R.; McDonald, A.; Fleming, M.D. The Steap proteins are metalloreductases. Blood, 2006, 108(4), 1388-1394.
57. Stoesz, S.P.; Friedl, A.; Haag, J.D.; Lindstrom, M.J.; Clark, G.M.; Gould, M.N. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int. J. Canc., 1998, 79(6), 565-572.
58. Furutani, M.; Arii, S.; Mizumoto, M.; Kato, M.; Imamura, M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Canc. Lett., 1998, 122(1-2), 209-214.
59. Nielsen, B.S.; Borregaard, N.; Bundgaard, J.R.; Timshel, S.; Sehested, M.; Kjeldsen, L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut, 1996, 38(3), 414-420.
60. Pinnix, Z.K.; Miller, L.D.; Wang, W.; D'Agostino, R., Jr.; Kute, T.; Willingham, M.C.; Hatcher, H.; Tesfay, L.; Sui, G.; Di, X.; Torti, S.V.; Torti, F.M. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med., 2010, 2(43), 43ra56.
61. Jiang, X.P.; Elliott, R.L.; Head, J.F. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticanc. Res., 2010, 30(3), 759-765.
62. Hockel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Canc. Inst., 2001, 93(4), 266-276.
63. Appleton, S.D.; Marks, G.S.; Nakatsu, K.; Brien, J.F.; Smith, G.N.; Graham, C.H.; Lash, G.E. Effects of hypoxia on heme oxygenase expression in human chorionic villi explants and immortalized trophoblast cells. Am. J. Physiol. Heart Circ. Physiol., 2003, 284(3), H853-858.
64. Liu, Y.L.; Ang, S.O.; Weigent, D.A.; Prchal, J.T.; Bloomer, J.R. Regulation of ferrochelatase gene expression by hypoxia. Life Sci., 2004, 75(17), 2035-2043.
65. Shaw, G.C.; Cope, J.J.; Li, L.; Corson, K.; Hersey, C.; Ackermann, G.E.; Gwynn, B.; Lambert, A.J.; Wingert, R.A.; Traver, D.; Trede, N.S.; Barut, B.A.; Zhou, Y.; Minet, E.; Donovan, A.; Brownlie, A.; Balzan, R.; Weiss, M.J.; Peters, L.L.; Kaplan, J.; Zon, L.I.; Paw, B.H. Mitoferrin is essential for erythroid iron assimilation. Nature, 2006, 440(7080), 96-100.
66. Kaneko, K.; Furuyama, K.; Aburatani, H.; Shibahara, S. Hypoxia induces erythroid-specific 5-aminolevulinate synthase expression in human erythroid cells through transforming growth factor-beta signaling. FEBS J., 2009, 276(5), 1370-1382.
67. Lok, C.N.; Ponka, P. Identification of a hypoxia response element in the transferrin receptor gene. J. Biol. Chem., 1999, 274(34), 24147-24152.
68. Adamec, J.; Rusnak, F.; Owen, W.G.; Naylor, S.; Benson, L.M.; Gacy, A.M.; Isaya, G. Iron-dependent self-assembly of recombinant yeast frataxin: Implications for Friedreich ataxia. Am. J. Human Genet., 2000, 67(3), 549-562.
69. Andriopoulos, B.; Hegedusch, S.; Mangin, J.; Riedel, H.D.; Hebling, U.; Wang, J.; Pantopoulos, K.; Mueller, S. Sustained hydrogen peroxide induces iron uptake by transferrin receptor-1 independent of the iron regulatory protein/iron-responsive element network. J. Biol. Chem., 2007, 282(28), 20301-20308.
70. Wang, D.; Wang, L.H.; Zhao, Y.; Lu, Y.P.; Zhu, L. Hypoxia regulates the ferrous iron uptake and reactive oxygen species level via divalent metal transporter 1 (DMT1) Exon1B by hypoxiainducible factor-1. IUBMB Life, 2010, 62(8), 629-636.
71. Shah, Y.M.; Matsubara, T.; Ito, S.; Yim, S.H.; Gonzalez, F.J. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metabol., 2009, 9(2), 152-164.
72. Mastrogiannaki, M.; Matak, P.; Keith, B.; Simon, M.C.; Vaulont, S.; Peyssonnaux, C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J. Clin. Investig., 2009, 119(5), 1159-1166.
73. Peyssonnaux, C.; Zinkernagel, A.S.; Schuepbach, R.A.; Rankin, E.; Vaulont, S.; Haase, V.H.; Nizet, V.; Johnson, R.S. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Investig., 2007, 117(7), 1926-1932.
74. Choi, S.O.; Cho, Y.S.; Kim, H.L.; Park, J.W. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem. Biophys. Res. Commun., 2007, 356(1), 312-317.
75. Norrby, K. Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelial growth factor A in vivo. J. Vascul. Res., 2004, 41(4), 293-304.
76. Lumsden, A.L.; Henshall, T.L.; Dayan, S.; Lardelli, M.T.; Richards, R.I. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Human Mol. Genet., 2007, 16(16), 1905-1920.
77. Torti, S.V.; Torti, F.M.; Whitman, S.P.; Brechbiel, M.W.; Park, G.; Planalp, R.P. Tumor cell cytotoxicity of a novel metal chelator. Blood, 1998, 92(4), 1384-1389.
78. Wallander, M.L.; Leibold, E.A.; Eisenstein, R.S. Molecular control of vertebrate iron homeostasis by iron regulatory proteins. Biochim. Biophys. Acta, 2006, 1763(7), 668-689.
79. Sanchez, M.; Galy, B.; Muckenthaler, M.U.; Hentze, M.W. Ironregulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat. Struc. Mol. Biol., 2007, 14(5), 420-426.
80. Ding, H.; Yan, C.Z.; Shi, H.; Zhao, Y.S.; Chang, S.Y.; Yu, P.; Wu, W.S.; Zhao, C.Y.; Chang, Y.Z.; Duan, X.L. Hepcidin is involved in iron regulation in the ischemic brain. PloS One, 2011, 6(9), e25324.
81. Corna, G.; Campana, L.; Pignatti, E.; Castiglioni, A.; Tagliafico, E.; Bosurgi, L.; Campanella, A.; Brunelli, S.; Manfredi, A.A.; Apostoli, P.; Silvestri, L.; Camaschella, C.; Rovere-Querini, P. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica, 2010, 95(11), 1814-1822.
82. Tesfay, L.; Huhn, A.J.; Hatcher, H.; Torti, F.M.; Torti, S.V. Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells. PLoS One, 2012, 7(7), e40030.
83. Robbins, E.; Pederson, T. Iron: its intracellular localization and possible role in cell division. Proc. Natl. Acad. Sci. USA, 1970, 66(4), 1244-1251.
84. Le, N.T.; Richardson, D.R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta, 2002, 1603(1), 31-46.
85. Trowbridge, I.S.; Lopez, F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA, 1982, 79(4), 1175-1179.
86. Thelander, L.; Reichard, P. Reduction of ribonucleotides. Annu. Rev. Biochem., 1979, 48, 133-158.
87. Kicic, A.; Chua, A.C.; Baker, E. Effect of iron chelators on proliferation and iron uptake in hepatoma cells. Cancer, 2001, 92(12), 3093-3110.
88. Kolberg, M.; Strand, K.R.; Graff, P.; Andersson, K.K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta, 2004, 1699(1-2), 1-34.
89. Thelander, L.; Graslund, A.; Thelander, M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun., 1983, 110(3), 859-865.
90. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol., 2004, 20, 781-810.
91. Radulescu, S.; Brookes, M.J.; Salgueiro, P.; Ridgway, R.A.; McGhee, E.; Anderson, K.; Ford, S.J.; Stones, D.H.; Iqbal, T.H.; Tselepis, C.; Sansom, O.J. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep., 2012, 2(2), 270-282.
92. Konijn, A.M.; Glickstein, H.; Vaisman, B.; Meyron-Holtz, E.G.; Slotki, I.N.; Cabantchik, Z.I. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood, 1999, 94(6), 2128-2134.
93. Cai, C.X.; Birk, D.E.; Linsenmayer, T.F. Nuclear ferritin protects DNA from UV damage in corneal epithelial cells. Mol. Biol. Cell, 1998, 9(5), 1037-1051.
94. Wong, A.; Yang, J.; Cavadini, P.; Gellera, C.; Lonnerdal, B.; Taroni, F.; Cortopassi, G. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Human Mol. Genet., 1999, 8(3), 425-430.
95. Tan, G.; Chen, L.S.; Lonnerdal, B.; Gellera, C.; Taroni, F.A.; Cortopassi, G.A. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Human Mol Genet., 2001, 10(19), 2099-2107.
96. Boddaert, N.; Le Quan Sang, K.H.; Rotig, A.; Leroy-Willig, A.; Gallet, S.; Brunelle, F.; Sidi, D.; Thalabard, J.C.; Munnich, A.; Cabantchik, Z.I. Selective iron chelation in Friedreich ataxia: Biologic and clinical implications. Blood, 2007, 110(1), 401-408.
97. Neilands, J.B. Siderophores: structure and function of microbial iron transport compounds. J. Biol. Chem., 1995, 270(45), 26723-26726.
98. Kalinowski, D.S.; Richardson, D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev., 2005, 57(4), 547-583.
99. Hider, R.C.; Zhou, T. The design of orally active iron chelators. Ann. NY Acad. Sci., 2005, 1054, 141-154.
100. Beutler, E. Iron storage disease: Facts, fiction and progress. Blood Cells Molecul. Dis., 2007, 39(2), 140-147.
101. Hatcher, H.C.; Singh, R.N.; Torti, F.M.; Torti, S.V. Synthetic and natural iron chelators: Therapeutic potential and clinical use. Fut. Medic. Chem., 2009, 1(9), 1643-1670.
102. Daniels, T.R.; Bernabeu, E.; Rodriguez, J.A.; Patel, S.; Kozman, M.; Chiappetta, D.A.; Holler, E.; Ljubimova, J.Y.; Helguera, G.; Penichet, M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta, 2012, 1820(3), 291-317.
103. Ohgami, R.S.; Campagna, D.R.; Greer, E.L.; Antiochos, B.; McDonald, A.; Chen, J.; Sharp, J.J.; Fujiwara, Y.; Barker, J.E.; Fleming, M.D. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet., 2005, 37(11), 1264-1269.
104. Vermylen, C. What is new in iron overload? Eur. J. Pediat., 2008, 167(4), 377-381.
105. Reeder, B.J.; Hider, R.C.; Wilson, M.T. Iron chelators can protect against oxidative stress through ferryl heme reduction. Free Rad. Biol. Med., 2008, 44(3), 264-273.
106. Cappellini, M.D.; Cohen, A.; Piga, A.; Bejaoui, M.; Perrotta, S.; Agaoglu, L.; Aydinok, Y.; Kattamis, A.; Kilinc, Y.; Porter, J.; Capra, M.; Galanello, R.; Fattoum, S.; Drelichman, G.; Magnano, C.; Verissimo, M.; Athanassiou-Metaxa, M.; Giardina, P.; Kourakli-Symeonidis, A.; Janka-Schaub, G.; Coates, T.; Vermylen, C.; Olivieri, N.; Thuret, I.; Opitz, H.; Ressayre-Djaffer, C.; Marks, P.; Alberti, D. A phase 3 study of deferasirox (ICL670), a oncedaily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107(9), 3455-3462.
107. Piga, A.; Galanello, R.; Forni, G.L.; Cappellini, M.D.; Origa, R.; Zappu, A.; Donato, G.; Bordone, E.; Lavagetto, A.; Zanaboni, L.; Sechaud, R.; Hewson, N.; Ford, J.M.; Opitz, H.; Alberti, D. Randomized phase II trial of deferasirox (Exjade, ICL670), a oncedaily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, 91(7), 873-880.
108. Vichinsky, E. Clinical application of deferasirox: Practical patient management. Am. J. Hematol., 2008, 83(5), 398-402.
109. Yang, L.P.; Keam, S.J.; Keating, G.M. Deferasirox: A review of its use in the management of transfusional chronic iron overload. Drugs, 2007, 67(15), 2211-2230.
110. Maggio, A. Light and shadows in the iron chelation treatment of haematological diseases. Brit. J. Haematol., 2007, 138(4), 407-421.
111. Delea, T.E.; Edelsberg, J.; Sofrygin, O.; Thomas, S.K.; Baladi, J.F.; Phatak, P.D.; Coates, T.D. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion, 2007, 47(10), 1919-1929.
112. Zhao, R.; Planalp, R.P.; Ma, R.; Greene, B.T.; Jones, B.T.; Brechbiel, M.W.; Torti, F.M.; Torti, S.V. Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem. Pharmacol., 2004, 67(9), 1677-1688.
113. Hasinoff, B.B.; Hellmann, K.; Herman, E.H.; Ferrans, V.J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem., 1998, 5(1), 1-28.
114. Wadler, S.; Makower, D.; Clairmont, C.; Lambert, P.; Fehn, K.; Sznol, M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J. Clin. Oncol.: Offic. J. Am. Soc. Clin. Oncol., 2004, 22(9), 1553-1563.
115. Yu, Y.; Wong, J.; Lovejoy, D.B.; Kalinowski, D.S.; Richardson, D.R. Chelators at the cancer coalface: Desferrioxamine to Triapine and beyond. Clin. Canc. Res., 2006, 12(23), 6876-6883.
116. Debebe, Z.; Ammosova, T.; Jerebtsova, M.; Kurantsin-Mills, J.; Niu, X.; Charles, S.; Richardson, D.R.; Ray, P.E.; Gordeuk, V.R.; Nekhai, S. Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology, 2007, 367(2), 324-333.
117. Darnell, G.; Richardson, D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood, 1999, 94(2), 781-792.
118. Yuan, J.; Lovejoy, D.B.; Richardson, D.R. Novel di-2-pyridylderived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood, 2004, 104(5), 1450-1458.
119. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA, 2006, 103(40), 14901-14906.
120. Nick, H.; Allegrini, P.R.; Fozard, L.; Junker, U.; Rojkjaer, L.; Salie, R.; Niederkofler, V.; O'Reilly, T. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. Exp. Biol. Med. (Maywood), 2009, 234(5), 492-503.
121. Wadler, S.; Makower, D.; Clairmont, C.; Lambert, P.; Fehn, K.; Sznol, M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J. Clin. Oncol., 2004, 22(9), 1553-1563.
122. Blatt, J.; Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Canc. Res., 1987, 47(7), 1749-1750.
123. Estrov, Z.; Tawa, A.; Wang, X.H.; Dube, I.D.; Sulh, H.; Cohen, A.; Gelfand, E.W.; Freedman, M.H. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood, 1987, 69(3), 757-761.
124. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M.A.; Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Canc. Res., 1990, 50(16), 4929-4930.
125. Hann, H.W.; Stahlhut, M.W.; Rubin, R.; Maddrey, W.C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer, 1992, 70(8), 2051-2056.
126. Kemp, J.D.; Thorson, J.A.; Stewart, B.C.; Naumann, P.W. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: Evidence for a threshold model of iron deprivation toxicity. Canc. Res., 1992, 52(15), 4144-4148.
127. Aouad, F.; Florence, A.; Zhang, Y.; Collins, F.; Henry, C.; Ward, R.J.; Crichton, R.R. Evaluation of new iron chelators and their therapeutic potential. Inorganica Chim. Acta, 2002, 339, 470-480.
128. Richardson, D.R.; Tran, E.H.; Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 1995, 86(11), 4295-4306.
129. Finch, R.A.; Liu, M.; Grill, S.P.; Rose, W.C.; Loomis, R.; Vasquez, K.M.; Cheng, Y.; Sartorelli, A.C. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 2000, 59(8), 983-991.
130. Abeysinghe, R.D.; Greene, B.T.; Haynes, R.; Willingham, M.C.; Turner, J.; Planalp, R.P.; Brechbiel, M.W.; Torti, F.M.; Torti, S.V. p53-independent apoptosis mediated by tachpyridine, an anticancer iron chelator. Carcinogen., 2001, 22(10), 1607-1614.
131. Ohyashiki, J.H.; Kobayashi, C.; Hamamura, R.; Okabe, S.; Tauchi, T.; Ohyashiki, K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Canc. Sci., 2009, 100(5), 970-977.
132. Lui, G.Y.; Obeidy, P.; Ford, S.J.; Tselepis, C.; Sharp, D.M.; Jansson, P.J.; Kalinowski, D.S.; Kovacevic, Z.; Lovejoy, D.B.; Richardson, D.R. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol. Pharmacol., 2013, 83(1), 179-190.
133. Finch, R.A.; Liu, M.C.; Cory, A.H.; Cory, J.G.; Sartorelli, A.C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul., 1999, 39, 3-12.
134. Shao, J.; Zhou, B.; Di Bilio, A.J.; Zhu, L.; Wang, T.; Qi, C.; Shih, J.; Yen, Y. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Canc. Therapeu., 2006, 5(3), 586-592.
135. Chaston, T.B.; Lovejoy, D.B.; Watts, R.N.; Richardson, D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Canc. Res., 2003, 9(1), 402-414.
136. Yen, Y.; Margolin, K.; Doroshow, J.; Fishman, M.; Johnson, B.; Clairmont, C.; Sullivan, D.; Sznol, M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Canc. Chemother. Pharmacol., 2004, 54(4), 331-342.
137. Lovejoy, D.B.; Jansson, P.J.; Brunk, U.T.; Wong, J.; Ponka, P.; Richardson, D.R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Canc. Res., 2011, 71(17), 5871-5880.
138. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA, 2006, 103(40), 14901-14906.
139. Hoffmann, E.K.; Lambert, I.H. Ion channels and transporters in the development of drug resistance in cancer cells. Philos. Trans. R Soc. Lond. B Biol. Sci., 2014, 369(1638), 20130109.
140. Cunningham, M.J.; Macklin, E.A.; Neufeld, E.J.; Cohen, A.R. Complications of β-thalassemia major in North America. Blood, 2004, 104(1), 34-39.
141. Borgna-Pignatti, C.; Rugolotto, S.; De Stefano, P.; Zhao, H.; Cappellini, M.D.; Del Vecchio, G.C.; Romeo, M.A.; Forni, G.L.; Gamberini, M.R.; Ghilardi, R. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematolog., 2004, 89(10), 1187-1193.
142. Anderson, L.J.; Westwood, M.A.; Holden, S.; Davis, B.; Prescott, E.; Wonke, B.; Porter, J.B.; Malcolm W.J.; Pennell, D.J. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Brit. J. Haematol., 2004, 127(3), 348-355.
143. Bergeron, R.J.; Streiff, R.R.; Creary, E.A.; Daniels, R.D., Jr.; King, W.; Luchetta, G.; Wiegand, J.; Moerker, T.; Peter, H.H. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood, 1993, 81(8), 2166-2173.
144. Bergeron, R.J.; Wiegand, J.; Bharti, N.; McManis, J.S. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J. Medic. Chem., 2012, 55(16), 7090-7103.
145. Cappellini, M.D.; Cohen, A.; Piga, A.; Bejaoui, M.; Perrotta, S.; Agaoglu, L.; Aydinok, Y.; Kattamis, A.; Kilinc, Y.; Porter, J. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 2006, 107(9), 3455-3462.
146. Alavi, S.; Ebadi, M.; Ghazizadeh, F.; Arzanian, M.T.; Shamsian, B.; Abdollah Gorji, F. Efficacy and safety of deferasirox in betathalassemia major patients in Iran: A prospective study from a single referral center in Iran. Pediat. Hematol. Oncol., 2014, 31(1), 76-86.
147. Vichinsky, E.; Torres, M.; Minniti, C.P.; Barrette, S.; Habr, D.; Zhang, Y.; Files, B. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two-year results including pharmacokinetics and concomitant hydroxyurea. Am. J. Hematol., 2013, 88(12), 1068-1073.
148. El-Beshlawy, A.M.; El-Alfy, M.S.; Sari, T.T.; Chan, L.L.; Tricta, F. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. Eur. J. Haematol., 2014.
149. Liu, Y.; Cui, Y.; Shi, M.; Zhang, Q.; Wang, Q.; Chen, X. Deferoxamine promotes MDA-MB-231 cell migration and invasion through increased ROS-dependent HIF-1alpha accumulation. Cell Physiol. Biochem., 2014, 33(4), 1036-1046.
150. Taichman, R.S.; Cooper, C.; Keller, E.T.; Pienta, K.J.; Taichman, N.S.; McCauley, L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Canc. Res., 2002, 62(6), 1832-1837.
151. Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.M.; Sampath, J.; Morris, J.J.; Lagutina, I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; Sorrentino, B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med., 2001, 7(9), 1028-1034.
152. Ross, D.D.; Yang, W.; Abruzzo, L.V.; Dalton, W.S.; Schneider, E.; Lage, H.; Dietel, M.; Greenberger, L.; Cole, S.P.; Doyle, L.A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Nat. Canc. Instit., 1999, 91(5), 429-433.
153. Litman, T.; Brangi, M.; Hudson, E.; Fetsch, P.; Abati, A.; Ross, D.D.; Miyake, K.; Resau, J.H.; Bates, S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci., 2000, 113(Pt 11), 2011-2021.
154. Sarkadi, B.; Ozvegy-Laczka, C.; Nemet, K.; Varadi, A. ABCG2--a transporter for all seasons. FEBS Lett., 2004, 567(1), 116-120.
155. Wang, X.; Baba, M. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir. Chem. Chemother., 2005, 16(4), 213-216.
156. Gunter, K.; Toupet, C.; Schupp, T. Characterization of an ironregulated promoter involved in desferrioxamine B synthesis in Streptomyces pilosus: Repressor-binding site and homology to the diphtheria toxin gene promoter. J. Bacteriol., 1993, 175(11), 3295-3302.
157. Cornelissen, C.N.; Sparling, P.F. Iron piracy: Acquisition of transferrin-bound iron by bacterial pathogens. Mol. Microbiol., 1994, 14(5), 843-850.
158. Mietzner, T.A.; Morse, S.A. The role of iron-binding proteins in the survival of pathogenic bacteria. Ann. Rev. Nutrit., 1994, 14, 471-493.
159. Litwin, C.M.; Calderwood, S.B. Role of iron in regulation of virulence genes. Clin. Microbiol. Rev., 1993, 6(2), 137-149.
160. Ochsner, U.A.; Vasil, M.L. Gene repression by the ferric uptake regulator in Pseudomonas aeruginosa: Cycle selection of iron-regulated genes. Proc. Natl. Acad. Sci. USA, 1996, 93(9), 4409-4414.
161. Tsolis, R.M.; Baumler, A.J.; Stojiljkovic, I.; Heffron, F. Fur regulon of Salmonella typhimurium: Identification of new ironregulated genes. J. Bacteriol., 1995, 177(16), 4628-4637.
162. Yamamoto, Y.; Poole, L.B.; Hantgan, R.R.; Kamio, Y. An ironbinding protein, Dpr, from Streptococcus mutans prevents irondependent hydroxyl radical formation in vitro. J. Bacteriol., 2002, 184(11), 2931-2939.
163. Trenor, C.C., 3rd; Campagna, D.R.; Sellers, V.M.; Andrews, N.C.; Fleming, M.D. The molecular defect in hypotransferrinemic mice. Blood, 2000, 96(3), 1113-1118.
164. Zhao, R.; Goldman, I.D. Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol. Aspec. Med., 2013, 34(2-3), 373-385.
165. Hooda, J.; Cadinu, D.; Alam, M.M.; Shah, A.; Cao, T.M.; Sullivan, L.A.; Brekken, R.; Zhang, L. Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. PloS One, 2013, 8(5), e63402.
166. Howitt, J.; Gysbers, A.M.; Ayton, S.; Carew-Jones, F.; Putz, U.; Finkelstein, D.I.; Halliday, G.M.; Tan, S.-S. Increased Ndfip1 in the substantia nigra of Parkinsonian Brains is associated with elevated Iron levels. PloS One, 2014, 9(1), e87119.
167. Przybylkowski, A.; Gromadzka, G.; Czlonkowska, A. Polymorphisms of metal transporter genes DMT1 and ATP7A in Wilson's disease. J. Trace Elem. Med. Biol: Organ Soc. Miner. Trace Elem., 2014, 28(1), 8-12.
168. Radulescu, S.; Brookes, M.J.; Salgueiro, P.; Ridgway, R.A.; McGhee, E.; Anderson, K.; Ford, S.J.; Stones, D.H.; Iqbal, T.H.; Tselepis, C.; Sansom, O.J. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep., 2012, 2(2), 270-282.
169. Wu, X.N.; Su, D.; Wang, L.; Yu, F.L. Roles of the hepcidinferroportin axis and iron in cancer. Eur. J. Canc. Prevent: Offic. J. Eur. Canc. Prevent. Organis., 2014, 23(2), 122-133.
170. Burpee, T.; Mitchell, P.; Fishman, D.; Islam, S.; Nemeth, E.; Westerman, M.; Wessling-Resnick, M.; Grand, R.J. Intestinal ferroportin expression in pediatric Crohn's disease. Inflamm. Bowel Dis., 2011, 17(2), 524-531.
171. Chan, K.T.; Choi, M.Y.; Lai, K.K.; Tan, W.; Tung, L.N.; Lam, H.Y.; Tong, D.K.; Lee, N.P.; Law, S. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol. Rep., 2014, 31(3), 1296-1304.
172. Jiao, Y.; Wilkinson, J.T.; Christine P.E.; Buss, J.L.; Wang, W.; Planalp, R.; Torti, F.M.; Torti, S.V. Iron chelation in the biological activity of curcumin. Free Rad. Biol. Med., 2006, 40(7), 1152-1160.
173. Wang, Y.; Langer, N.B.; Shaw, G.C.; Yang, G.; Li, L.; Kaplan, J.; Paw, B.H.; Bloomer, J.R. Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria. Exp. Hematol., 2011, 39(7), 784-794.
174. Huang, M.L.; Becker, E.M.; Whitnall, M.; Suryo R.Y.; Ponka, P.; Richardson, D.R. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl. Acad. Sci. USA, 2009, 106(38), 16381-16386.
175. Guyatt, G.H.; Patterson, C.; Ali, M.; Singer, J.; Levine, M.; Turpie, I.; Meyer, R. Diagnosis of iron-deficiency anemia in the elderly. Am. J. Med., 1990, 88(3), 205-209.
176. Canonne-Hergaux, F.; Zhang, A.S.; Ponka, P.; Gros, P. Characterization of the iron transporter DMT1 (NRAMP2/DCT1) in red blood cells of normal and anemic mk/mk mice. Blood, 2001, 98(13), 3823-3830.
177. Propper, R.D.; Shurin, S.B.; Nathan, D.G. Reassessment of the use of desferrioxamine B in iron overload. New Eng. J. Med., 1976, 294(26), 1421-1423.
178. Pippard, M.J.; Callender, S.T.; Finch, C.A. Ferrioxamine excretion in iron-loaded man. Blood, 1982, 60(2), 288-294.
179. Xing, Y.; Hua, Y.; Keep, R.F.; Xi, G. Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. Brain Res., 2009, 1291, 113-121.
180. Ishizaka, N.; Saito, K.; Mori, I.; Matsuzaki, G.; Ohno, M.; Nagai, R. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler., Thrombo., Vascul. Biol., 2005, 25(11), 2282-2288.
181. Zhao, Y.; Rempe, D.A. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J. Cerebral Blood Flow Metabol., 2011, 31(6), 1412-1423.
182. Yamasaki, T.; Saeki, I.; Sakaida, I. Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments. Hepatol. Internatl., 2014, 1-7.
183. (a) Kicic, A.; Chua, A.C.; Baker, E. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents. Anti-canc. Drug Des., 2001, 16(4-5), 195-207
184. (b) Kicic, A.; Chua, A.C.; Baker, E. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine. Brit. J. Pharmacol., 2002, 135(6), 1393-1402.
185. Sajid, R.; Ghani, F.; Adil, S.; Khurshid, M. Oral iron chelation therapy with deferiprone in patients with Thalassemia Major. JPMA. J. Pak. Med. Assoc., 2009, 59(6), 388-390.
186. Christoforidis, A.; Perifanis, V.; Athanassiou-Metaxa, M. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. Brit. J. Haematol., 2006, 135(2), 271-272.
187. Christoforidis, A.; Perifanis, V.; Tsatra, I.; Vlachaki, E.; Athanassiou-Metaxa, M. Evolution of OGTT in patients with betathalassaemia major in relation to chelation therapy. Diabet. Res. Clin. Pract., 2007, 76(1), 6-11.
188. Farmaki, K.; Angelopoulos, N.; Anagnostopoulos, G.; Gotsis, E.; Rombopoulos, G.; Tolis, G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Brit. J. Haematol., 2006, 134(4), 438-444.
189. Molina-Holgado, F.; Gaeta, A.; Francis, P.T.; Williams, R.J.; Hider, R.C. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J. Neurochem., 2008, 105(6), 2466-2476.
190. Prasanthi, J.R.; Schrag, M.; Dasari, B.; Marwarha, G.; Dickson, A.; Kirsch, W.M.; Ghribi, O. Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J. Alzheimer's Dis., 2012, 30(1), 167-182.
191. Sattarahmady, N.; Heli, H.; Moosavi-Movahedi, A.A.; Karimian, K. Deferiprone: structural and functional modulating agent of hemoglobin fructation. Mol. Biol. Rep., 2014, 1-7.
192. Leanderson, P.; Tagesson, C. Iron bound to the lipophilic iron chelator, 8-hydroxyquinoline, causes DNA strand breakage in cultured lung cells. Carcinogen., 1996, 17(3), 545-550.
193. Jonas, S.K.; Riley, P.A. The effect of ligands on the uptake of iron by cells in culture. Cell Biochem. Funct., 1991, 9(4), 245-253.
194. Lescoat, G.; Leonce, S.; Pierre, A.; Gouffier, L.; Gaboriau, F. Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. Chemico-biol. Interac., 2012, 195(2), 165-172.
195. Corce, V.; Morin, E.; Guiheneuf, S.; Renault, E.; Renaud, S.; Cannie, I.; Tripier, R.; Lima, L.M.; Julienne, K.; Gouin, S.G.; Loreal, O.; Deniaud, D.; Gaboriau, F. Polyaminoquinoline iron chelators for vectorization of antiproliferative agents: Design, synthesis, and validation. Bioconjug. Chem., 2012, 23(9), 1952-1968.
196. Antequera, D.; Bolos, M.; Spuch, C.; Pascual, C.; Ferrer, I.; Fernandez-Bachiller, M.I.; Rodriguez-Franco, M.I.; Carro, E. Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Abeta accumulation and cell death: Involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiol. Dis., 2012, 46(3), 682-691.
197. Balducci, L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer, 2006, 106(10), 2087-2094.
198. Chaudhary, P.; Pullarkat, V. Deferasirox: Appraisal of safety and efficacy in long-term therapy. J. Blood Med., 2013, 4, 101-110.
199. Turner, J.; Koumenis, C.; Kute, T.E.; Planalp, R.P.; Brechbiel, M.W.; Beardsley, D.; Cody, B.; Brown, K.D.; Torti, F.M.; Torti, S.V. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood, 2005, 106(9), 3191-3199.
200. Herman, E.H.; Ferrans, V.J. Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Canc. Treatm. Rev., 1990, 17(2), 155-160.
201. Swain, S.; Vici, P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. J. Canc. Res. Clin. Oncol., 2004, 130(1), 1-7.
202. Hasinoff, B.B.; Herman, E.H. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascu. Toxicol., 2007, 7(2), 140-144.
203. Shao, J.; Zhou, B.; Zhu, L.; Qiu, W.; Yuan, Y.-C.; Xi, B.; Yen, Y. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Canc. Res., 2004, 64(1), 1-6.
204. Barker, C.A.; Burgan, W.E.; Carter, D.J.; Cerna, D.; Gius, D.; Hollingshead, M.G.; Camphausen, K.; Tofilon, P.J. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin. Canc. Res., 2006, 12(9), 2912-2918.
205. Becker, E.M.; Lovejoy, D.B.; Greer, J.M.; Watts, R.; Richardson, D.R. Identification of the di--‐pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti--‐tumour agents. Brit. J. Pharmacol., 2003, 138(5), 819-830.
206. Chaston, T.B.; Watts, R.N.; Yuan, J.; Richardson, D.R. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Canc. Res., 2004, 10(21), 7365-7374.
207. Debebe, Z.; Ammosova, T.; Jerebtsova, M.; Kurantsin-Mills, J.; Niu, X.; Charles, S.; Richardson, D.R.; Ray, P.E.; Gordeuk, V.R.; Nekhai, S. Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology, 2007, 367(2), 324-333.
208. Jiao, Y.; Wilkinson, J.; Di, X.; Wang, W.; Hatcher, H.; Kock, N.D.; D'Agostino, R.; Knovich, M.A.; Torti, F.M.; Torti, S.V. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood, 2009, 113(2), 462-469.
209. Tiwari, S.K.; Agarwal, S.; Seth, B.; Yadav, A.; Nair, S.; Bhatnagar, P.; Karmakar, M.; Kumari, M.; Chauhan, L.K.S.; Patel, D.K. Curcumin loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano, 2014.
210. Gupta, S.C.; Patchva, S.; Aggarwal, B.B. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J., 2013, 15(1), 195-218.
211. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.; Torti, S. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci., 2008, 65(11), 1631-1652.
212. Gururaj, A.E.; Belakavadi, M.; Venkatesh, D.A.; Marmé, D.; Salimath, B.P. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem. Biophys. Res. Commun., 2002, 297(4), 934-942.
213. Farombi, E.O.; Nwaokeafor, I.A. Anti-oxidant mechanisms of kolaviron: Studies on serum lipoprotein oxidation, metal chelation and oxidative membrane damage in rats. Clin. Exp. Pharmacol. Physiol., 2005, 32(8), 667-674.
214. Samuel, T.; Fadlalla, K.; Mosley, L.; Katkoori, V.; Turner, T.; Manne, U. Dual-mode interaction between quercetin and DNAdamaging drugs in cancer cells. Anticanc. Res., 2012, 32(1), 61-71.
215. Chan, S.-T.; Yang, N.-C.; Huang, C.-S.; Liao, J.-W.; Yeh, S.-L. Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PloS One, 2013, 8(1), e54255.
216. Jeong, J.H.; An, J.Y.; Kwon, Y.T.; Rhee, J.G.; Lee, Y.J. Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J. Cell. Biochem., 2009, 106(1), 73-82.
217. Chang, Y.-C.; Lee, T.-S.; Chiang, A.-N. Quercetin enhances ABCA1 expression and cholesterol efflux through a p38-dependent pathway in macrophages. J. Lipid Res., 2012, 53(9), 1840-1850.
218. Chen, J.Y.; Hu, R.Y.; Chou, H.C. Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J. Biomed. Sci., 2013, 20, 95.
219. Xu, F.; Proft, J.; Gibbs, S.; Winkfein, B.; Johnson, J.N.; Syed, N.; Braun, J.E. Quercetin targets cysteine string protein (CSPalpha) and impairs synaptic transmission. PloS One, 2010, 5(6), e11045.
220. Larson, A.J.; Symons, J.D.; Jalili, T. Therapeutic potential of quercetin to decrease blood pressure: Review of efficacy and mechanisms. Adv. Nutrit.: Internat. Rev. J., 2012, 3(1), 39-46.
221. Aktas, O.; Prozorovski, T.; Smorodchenko, A.; Savaskan, N.E.; Lauster, R.; Kloetzel, P.M.; Infante-Duarte, C.; Brocke, S.; Zipp, F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol., 2004, 173(9), 5794-5800.
222. Weinreb, O.; Amit, T.; Youdim, M.B. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Rad. Biol. Med., 2007, 43(4), 546-556.
223. Mandel, S.; Weinreb, O.; Reznichenko, L.; Kalfon, L.; Amit, T., Green tea catechins as brain-permeable, non toxic iron chelators to “iron out iron” from the brain. In Oxidative Stress and Neuroprotection, Springer: 2006; pp 249-257.
224. Hurrell, R.F.; Juillerat, M.A.; Reddy, M.B.; Lynch, S.R.; Dassenko, S.A.; Cook, J.D. Soy protein, phytate, and iron absorption in humans. Am. J. Clin. Nutrit., 1992, 56(3), 573-578.
225. Hanson, L.N.; Engelman, H.M.; Alekel, D.L.; Schalinske, K.L.; Kohut, M.L.; Reddy, M.B. Effects of soy isoflavones and phytate on homocysteine, C-reactive protein, and iron status in postmenopausal women. Am. J. Clin. Nutrit., 2006, 84(4), 774-780.
226. Davis, J.; Higginbotham, A.; O'Connor, T.; Moustaid-Moussa, N.; Tebbe, A.; Kim, Y.C.; Cho, K.W.; Shay, N.; Adler, S.; Peterson, R.; Banz, W. Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Annals Nutrit. Metabol., 2007, 51(1), 42-52.